CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
研究型高级实践提供者在 CAR-T 细胞临床试验中的作用
英文原题：The Role of the Research Advanced Practice Provider in CAR T-Cell Clinical Trials.
查看英文原题
The Role of the Research Advanced Practice Provider in CAR T-Cell Clinical Trials.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
近年来，嵌合抗原受体（CAR）T细胞疗法已成为治疗难治性淋巴瘤和多发性骨髓瘤患者的有效且可能改变治疗范式的疗法。该新型疗法通过工程化改造T细胞，使其能够识别癌细胞表面的特定抗原。大量临床试验促使美国食品药品监督管理局批准了多种CAR-T 细胞产品。鉴于这些研究的复杂性，以及CAR-T 细胞治疗患者需要高水平照护，研究型高级执业医务人员（APP）已成为CAR-T 细胞临床试验成功的关键。本综述探讨研究型APP在CAR-T 细胞临床试验中的重要作用。
展开英文摘要原文
In recent years, chimeric antigen receptor (CAR) T-cell therapy has emerged as an effective and potentially paradigm-shifting therapy for patients with refractory lymphoma and myeloma. This novel therapy involves engineering T cells to recognize specific antigens on the surface of cancer cells. Several CAR T-cell products are approved by the US Food and Drug Administration as a result of numerous clinical trials.
Due to the complexity of these studies and the high level of care required for CAR T-cell therapy patients, the role of the research advanced practice provider (APP) has become increasingly central to the success of CAR T-cell trials. This review article explores the vital role of the research APP in CAR T-cell clinical trials.
论文信息
- 作者
- Dsouza L
- 单位
- The University of Texas MD Anderson Cancer Center, Houston, Texas.United States
- 文献类型
- 综述
- 期刊
- Journal of the advanced practitioner in oncology2023 Jan
- 原文标识
- PubMed 36741214 · DOI 10.6004/jadpro.2023.14.1.5
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →